Intestinal inflammation-induced child growth failure: immunologic and endocrine mechanisms
MA Jing-Qiu, SHENG Xiao-Yang
Department of Child and Adolescent Health Care, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Institute for Pediatric Research; Shanghai Key Laboratory of Children′s Environment Health, Shanghai 200092, China. shengxiaoyangcn@yahoo.com.cn
［1］Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood in-ammatory bowel disease［J］. Inamm Bowel Dis, 2008, 14(6): 839-849.
［2］Wong SC, MacRae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation［J］. J Pediatr Gastroenterol Nutr, 2006, 43(2): 144-155.
［3］Ahmed SF, S-vendahl L. Promoting growth in chronic inflammatory disease: lessons from studies of the growth plate［J］. Horm Res, 2009, 72(Suppl 1):42-47.
［4］Shono T, Kato M, Aoyagi Y, Haruna H, Fujii T, Kudo T, et al. Assessment of growth disturbance in Japanese children with IBD［J］. Int J Pediatr, 2010, 2010: 958915.
［5］Walenkamp MJ, Wit JM. Genetic disorders in the GH IGF-I axis in mouse and man［J］. Eur J Endocrinol, 2007,157 (Suppl 1): S15-S26.
［6］MacRae VE, Wong SC, Farquharson C, Ahmed SF. Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (Review)［J］. Int J Mol Med, 2006, 18(6): 1011-1018.
［7］Lunn PG. The impact of infection and nutrition on gut function and growth in childhood［J］. Proc Nutr Soc, 2000, 59(1):147-154.
［8］Campbell DI, Elia M, Lunn PG. Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation［J］. J Nutr, 2003, 133(5): 1332-1338.
［9］The WHO Child Growth Standards［DB/OL］. ［May 19, 2011］ Available at http://www.who.int/child growth/en/.
［10］Panter-Brick C, Lunn PG, Langford RM, Maharjan M, Manandhar DS. Pathways leading to early growth faltering: an investigation into the importance of mucosal damage and immunostimulation in different socio-economic groups in Nepal［J］. Br J Nutr, 2009, 101(4):558-567.
［13］Fagerberg UL, Loof L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease［J］. JPGN, 2007, 45(4): 414-420.
［14］Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease［J］. Dig Liver Dis, 2008, 40(7): 547-553.
［15］Baldassarre ME, Fanelli M, Lasorella ML, Laneve A, Crosso R, Falone MR, et al. Fecal calprotectin (FC) in newborns: is it a predictive marker of gastrointestinal and/or allergic disease?［J］. Immunopharmacol Immunotoxicol, 2011, 33(1):220-223.
［16］Baldassarre ME, Altomare MA, Fanelli M, Cabone D, Di Bitonto G, Mautone A, et al. Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease?［J］. Endocr Metab Immune Disord Drug Targets, 2007, 7(1):1-5.
［17］Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease［J］. Dig Liver Dis, 2009, 41(1):56-66.
［18］Quail MA, Russell RK, Van Limbergen JE, Roqers P, Drummond HE, Wilson DC, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood in-ammatory bowel disease［J］. In-amm Bowel Dis, 2009, 15(5):756-759.
［19］Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kuqathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric in-ammatory bowel disease［J］. Inflamm Bowel Dis, 2008, 14(5):669-673.
［20］Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn′s disease［J］. Cochrane Database Syst Rev, 2005, 3:CD003873.
［22］Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn′s disease: pathogenesis and interventions［J］. Inflamm Bowel Dis, 2007, 13(5):620-628.
［23］Grottrup-Wolfers E, Moeller J, Karbach U, Muller-Lissner S, Endres S. Elevated cell-associated levels of interleukin 1β and interleukin 6 in inflamed mucosa of inflammatory bowel disease［J］.Eur J Clin Invest, 1996, 26(2):115-122.
［24］Street ME, de′Angelis G, Camacho-Hübner C, Giovannelli G, Ziveri MA, Bacchini PL, et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease［J］.Horm Res, 2004, 61(4): 159-164.
［25］Raddatz D, Bockemühl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome［J］. Eur J Gastroenterol Hepatol. 2005, 17(5):547-557.
［26］Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth［J］. Dev Biol, 2001, 229(1): 141-162.
［27］Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton［J］. Endocr Rev, 2008, 29(5):535-559.
［28］Buzzelli MD, Nagarajan M, Radtka JF, Shumate ML, Navaratnarajah M, Lang CH, et al. Nuclear factor-kappa B mediates the inhibitory effects of tumor necrosis factor-alpha on growth hormone-inducible gene expression in liver［J］. Endocrinology, 2008, 149(12): 6378-6388.
［29］Parker EA, Hegde A, Buckley M, Barnes KM, Baron J, Nilsson O. Spatial and temporal regulation of GH-IGF-related gene expression in growth plate cartilage［J］. J Endocrinol, 2007, 194(1): 31-40.
［30］Ahmed SF, Farquharson C. The effect of GH and IGF1 on linear growth and skeletal development and their modulation by SOCS proteins［J］. J Endocrinol, 2010, 206(3):249-259.
［31］Mackie EJ, Ahmed YA, Tatarczuch L, Chen KS, Mirams M. Endochondral ossification: how cartilage is converted into bone in the developing skeleton［J］. Int J Biochem Cell Biol, 2008, 40(1): 46-62.
［32］Shapiro IM, Adams CS, Freeman T, Srinivas V. Fate of the hypertrophic chondrocyte: microenvironmental perspectives on apoptosis and survival in the epiphyseal growth plate［J］. Birth Defects Res C Embryo Today, 2005, 75(4):330-339.
［33］Klammt J, Pf-ffle R, Werner H, Kiess W. IGF signaling defects as causes of growth failure and IUGR［J］. Trends Endocrinol Metab, 2008, 19(6):197-205.
［34］Nilsson O, Mitchum RD Jr, Schrier L, Ferns SP, Barnes KM, Troendle JF, et al. Growth plate senescence is associated with loss of DNA methylation［J］. J Endocrinol, 2005, 186(1):241-249.
［35］Frost RA, Nystrom GJ, Lang CH. Stimulation of insulin-like growth factor binding protein-1 synthesis by interleukin-1 beta: requirement of the mitogen-activated protein kinase pathway［J］. Endocrinology, 2000, 141(9): 3156-3164.
［36］Pass C, MacRae VE, Ahmed SF, Farquharson C. In-ammatory cytokines and the GH/IGF-I axis: novel actions on bone growth［J］. Cell Biochem Funct, 2009, 27(3):119-127.
［37］Shumate ML, Yumet G, Ahmed TA, Cooney RN. Interleukin-1 inhibits the induction of insulin-like growth factor-I by growth hormone in CWSV-1 hepatocytes［J］. Am J Physiol Gastrointest Liver Physiol, 2005, 289(2): G227-G239.
［38］Katsanos KH, Tsianos EV. Insulinlike growth factor system and inflammatory bowel disease［J］. Ann Gastroenterol, 2002, 15(1):11-17.
［39］Ahmed TA, Buzzelli MD, Lang CH, Capen JB, Shumate ML, Navaratnarajah M, et al. Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes［J］. Am J Physiol Gastrointest Liver Physiol, 2007, 292(6): G1793-G1803.
［40］De Pascalis B, Bianchi A, Satta MA, Lupascu A, Mentella MC, Leo D, et al. Growth hormone in inflammatory bowel disease［J］. Eur Rev Med Pharmacol Sci, 2006, 10(1):13-16.
［41］De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, et al. Effects of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis［J］. Endocrinology, 2001, 142(11):4818-4826.
［42］Sawczenko A, Azooz O, Paraszczuk J, Idestrom M, Croft NM, Savage MO, et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the174 IL-6 G/C polymorphism in children［J］. PNAS, 2005, 102(37):13260-13265.
［43］Theiss AL, Fruchtman S, Lund PK. Growth factors in inflammatory bowel disease: the actions and interactions of growth hormone and insulin-like growth factor-I［J］. Inflamm Bowel Dis, 2004, 10(6):871-880.
［44］Ahmed T, Gladys Y, Margaret S, Lang CH, Rotwein P, Cooney RN. Tumor necrosis factor inhibits growth hormone-mediated gene expression in hepatocytes［J］. Am J Physiol Gastrointest Liver Physiol, 2006, 291(1): G35-G44.
［45］Yumet G, Shumate ML, Bryant P, Lin CM, Lang CH, Cooney RN. Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis［J］. Am J Physiol Endocrinol Metab, 2002, 283(3):E472-E481.
［46］Macrae VE, Farquharson C, Ahmed SF. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to proinammatory cytokines［J］. J Endocrinol, 2006, 189: 319-328.
［47］Mortensson K, Chrysis D, Sovendahl L. Interleukin-1β and TNF-α act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones［J］. J Bone Miner Res, 2004, 19(11):1805-1812.
［48］Broussard SR, McCusker RH, Novakofski JE, Strle K, Shen WH, Johnson RW, et al. IL-1 beta impairs insulin-like growth factor i-induced differentiation and downstream activation signals of the insulin-like growth factor i receptor in myoblasts［J］. J Immunol, 2004, 172(12):7713-7720.
［49］Strle K, Broussard SR, McCusker RH, Shen WH, Johnson RW, Freund GG, et al. Proinflammatory cytokine impairment of insulin-like growth factor I-induced protein synthesis in skeletal muscle myoblasts requires ceramide［J］. Endocrinology, 2004, 145(10):4592-4602.
［50］Macrae VE, Ahmed SF, Mushtaq T, Farquharson C. IGF-I signalling in bone growth: inhibitory actions of dexamethasone and IL-1beta［J］. Growth Horm IGF Res, 2007, 17(5):435-439.
［51］Shi H, Tzameli I, Bjorbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling［J］. J Biol Chem, 2004, 279(33): 34733-34740.
